Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases
Novartis has entered into a global license agreement with Kyorin Pharmaceutical for KRP-M223, an MRGPRX2 antagonist targeting allergic and inflammatory diseases34.
The deal includes an upfront payment of $55 million from Novartis to Kyorin, with potential milestone payments of up to $777.5 million and tiered royalties on net sales34.
KRP-M223 is currently in the pre-clinical stage and is being developed for conditions such as chronic spontaneous urticaria4.
Novartis gains exclusive worldwide rights to develop, manufacture, and commercialize KRP-M223, while Kyorin retains an option to commercialize the product in Japan4.
The agreement allows Kyorin to potentially manufacture the product for the Japanese market, with Novartis retaining an option to co-promote with Kyorin in Japan4.
This deal comes as Novartis faces competition from Dupixent (dupilumab) in the allergic and inflammatory disease space7.
Chronic spontaneous urticaria, one of the target indications for KRP-M223, affects approximately 40 million people worldwide and can significantly impact patients' quality of life4.
The licensing of KRP-M223 aligns with Kyorin's long-term vision "Vision 110" to create high-value new drugs that meet medical needs and contribute to global health4.
Sources:
3. https://www.tipranks.com/news/company-announcements/kyorin-and-novartis-forge-global-license-agreement-for-krp-m223
4. https://www.kyorin-pharm.co.jp/en/news/docs/KYORIN%20and%20Novartis%20Enter%20into%20a%20Global%20License%20Agreement%20for%20KRP-M223.pdf